Last Updated Last Updated : May 17, 2021 / 10:46 AM IST | Source: Moneycontrol.com

Cipla — While COVID scope continues, watch out for FY23

Just when it seemed that Covid tailwinds are waning for Cipla, the drug maker has repositioned itself for the opportunities emerging from the second wave of the pandemic

Anubhav Sahu

To view the full content of this article, you have to be a Pro:

  • Already a Moneycontrol Pro subscriber?
  • Not a Moneycontrol Pro subscriber yet?

Subscribe to Moneycontrol Pro:

What's included:

  • Ad free experience across Platforms
  • 230+ exclusive stories per month
  • Sharpest Opinions & Actionable Insights
  • Exclusive Research & Expert Technical Analysis
  • Daily Newsletter
  • 20+ Technical Picks every week
  • Recovery Tracker
  • Exclusive webinars on varied topics
  • Weekly wrap up and much more!!!